AI Article Synopsis

  • A study reviewed medical records from 1,426 imaging exams, finding that 39.8% had incidental findings (IFs), with a higher prevalence in older participants and certain imaging types like abdominopelvic CT.
  • Out of the exams with IFs, only 6.2% led to clinical action, resulting in clear medical benefits for 1.1% of patients and some medical burden for a small fraction.
  • The research highlights that while IFs are common, their medical significance varies greatly by imaging method and patient demographics, suggesting the need for careful evaluation by radiologists.

Article Abstract

Background: Little information exists concerning the frequency and medical significance of incidental findings (IFs) in imaging research.

Methods: Medical records of research participants undergoing a research imaging examination interpreted by a radiologist during January through March 2004 were reviewed, with 3-year clinical follow-up. An expert panel reviewed all IFs generating clinical action to determine medical benefit/burden on the basis of predefined criteria. The frequency of IFs that generated further clinical action was estimated by modality, body part, age, and sex, along with net medical benefit or burden.

Results: Of 1426 research imaging examinations, 567 (39.8%) had at least 1 IF (1055 total). Risk of an IF increased significantly by age (odds ratio [OR], 1.5; 95% confidence interval, 1.4-1.7 per decade increase). Abdominopelvic computed tomography generated more IFs than other examinations (OR, 18.9 vs ultrasonography; 9.2% with subsequent clinical action), with computed tomography of the thorax and magnetic resonance imaging of the head next (OR, 11.9 and 5.9; 2.8% and 2.2% with action, respectively). Of the 567 examinations with an IF, 35 (6.2%) generated clinical action, resulting in clear medical benefit in 1.1% (6 of 567) and clear medical burden in 0.5% (3 of 567). Medical benefit/burden was usually unclear (26 of 567 [4.6%]).

Conclusions: Frequency of IFs in imaging research examinations varies significantly by imaging modality, body region, and age. Research imaging studies at high risk for generating IFs can be identified. Routine evaluation of research images by radiologists may result in identification of IFs in a high number of cases and subsequent clinical action to address them in a small but significant minority. Such clinical action can result in medical benefit to a small number of patients.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3721142PMC
http://dx.doi.org/10.1001/archinternmed.2010.317DOI Listing

Publication Analysis

Top Keywords

clinical action
24
medical benefit
12
incidental findings
8
imaging
8
medical
8
ifs imaging
8
medical benefit/burden
8
frequency ifs
8
generated clinical
8
modality body
8

Similar Publications

Objectives: This study reviews literature on the psychiatric effects of delta-8-THC, particularly psychosis and severe mental health outcomes, to highlight the need for further research and regulation.

Background: Marijuana, the most widely used illicit drug in the United States, sees increasing use due to legalization. Although moderate use is generally safe, adverse effects can occur, especially in those with preexisting conditions.

View Article and Find Full Text PDF

Engineered Microneedle System Enables the Smart Regulation of Nanodynamic Sterilization and Tissue Regeneration for Wound Management.

Adv Sci (Weinh)

January 2025

Department of Laboratory Medicine, School of Chemical Science and Engineering, Shanghai Tenth People's Hospital of Tongji University, Tongji University, Shanghai, 200092, P. R. China.

The healing of bacterial biofilm-infected wounds is a complex process, and the construction of emerging therapeutic modalities that regulate the microenvironment to magnify therapeutic effects and reduce biotoxicity is still highly challenging. Herein, an engineered microneedle (MN) patch is reported to mediate the efficient delivery of black phosphorus nanosheets (BP NSs) and copper peroxide nanodots (CP NDs) for dual nanodynamic sterilization and methicillin-resistant staphylococcus aureus (MRSA)-infected wound healing. Results demonstrate that the system can eliminate biofilm, reduce cytotoxicity, promote angiogenesis and tissue regeneration by the multiple advantages of chemodynamic therapy (CDT), enhanced photodynamic therapy (PDT), and improved degradation process from BP NSs to phosphate for promoting cell proliferation.

View Article and Find Full Text PDF

Association Between Diagnostic Delay and Economic and Clinical Burden in Axial Spondyloarthritis: A Multicentre Retrospective Observational Study.

Rheumatol Ther

January 2025

Rheumatology Department, Parc Taulí University Hospital. Institut d'Investigació i Innovació Parc Taulí (I3PT-CERCA), Universitat Autònoma de Barcelona, Parc Taulí, 1, Sabadell, 08208, Barcelona, Spain.

Introduction: Axial spondyloarthritis (axSpA) is a chronic inflammatory condition associated with considerable pain and impaired health-related quality of life (HRQoL) for affected patients. Despite the documented increase in healthcare resource utilization (HRU) related to axSpA, few studies have explored the impact of diagnostic delays on these outcomes. This study sought to determine the association between diagnostic delay of axial spondyloarthritis (axSpA) and costs in the 3 years after diagnosis.

View Article and Find Full Text PDF

Background: Data from observational and clinical studies indicate an association between skin microbiota and hidradenitis suppurativa (HS). However, the causal relationship between skin microbiota and HS remains to be elucidated.

Methods: We obtained data on skin microbiota and HS from summary statistics of genome-wide association studies and applied Mendelian randomization (MR) statistical methods to assess causality.

View Article and Find Full Text PDF

Background And Aims: Treating ulcerative colitis (UC) in patients with prior advanced therapy (AT) exposure may be challenging. We report the efficacy and safety of risankizumab, a monoclonal interleukin 23p19 antibody, in patients with UC and prior inadequate response or intolerance to AT (AT-IR).

Methods: In the 12-week phase 3 INSPIRE induction study, patients were randomized to intravenous risankizumab 1200 mg or placebo.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!